AWSensors host the 24-Month Meeting of LIQBIOPSENS EU project
The meeting of all the project partners was held in Valencia, Spain, at the headquarters of AWSensors and Sistemas Genómicos, where significant advances were presented between the project partners and important decisions were taken to successfully continue pursuing the project goals. Another whole year is still required to complete the project.
The consortium for the development of this project is composed of the following institutions: Servicio Andaluz de Salud (Spain), Université Catholique de Louvin (Belgium), Foundation for Research and Technology Hellas (Greec), DestiNA Genomics (UK, Spain), Sistemas Genómicos (Spain) and AWSensors (Spain). AWSesensor.
If you wish to know more about the LIQBIOPSENS project, visit the project website at http://liqbiopsens.com.
https://awsensors.com/wp-content/uploads/2015/05/Liqbiopsens-project-e1493811129481.jpg6671000AWSensorshttps://awsensors.com/wp-content/uploads/2015/07/Logos-AWS-2015-1.pngAWSensors2018-02-19 11:58:582020-01-23 09:51:06AWSENSORS HOSTS THE 24M MEETING OF LIQBIOPSENS EUROPEAN PROJECT
Swedish and Spanish companies invested in AWSensors seeing a growth opportunity.
AWSensors raised 1M€ investment round to strengthen its position in scientific market and enter the healthcare tech market, one of the most competitive markets. The company though has convinced Swedish and Spanish investors that the potential payoff is worth the risk.
Firms entering into the investment round were BAble Capital, a venture capital firm that aims to invest in technology-based companies from Spanish universities and research centers, and Tech Transfer UPV, a venture capital firm created specifically to transfer technology developed at the Spanish university, Polytechnic University of Valencia. But also a consortium of Swedish companies invested in AWSensors seeing a growth opportunity. Other Spanish companies like PolymerChar, Keodes or Citrosol are also among the shareholders.
AWSensors, led by Prof. Antonio Arnau, expects to speed up innovation processes to launch new scientific equipments to meet demand from scientists and industry R&D but also to develop cutting-edge healthcare technology to be applied in personalized medicine.
The aim of these new developments is to get a blood test meant to catch cancer when it’s most treatable, before patients show symptoms, by detecting fragments of DNA shed by tumors. A new liquid biopsy system will allow for detection of this circulating DNA and its mutations and will be an essential equipment to help doctors diagnose, monitor and treat cancer patients in a personalized way.
To hit that goal, AWSensors got another 1M€ from European Comission through two H2020 European projects:
LiqBiopSens project, that is coordinated by AWSensors and developed together with companies and institutions from Spain, Belgium, UK and Greece.
Catch-u-DNA project, which is carried out with partners from Germany, France, Israel, Greece and Spain.
These projects as a whole were funded with 5.7M€ by European Comission.
AWSENSORS CONSIGUE UNA INVERSIÓN DE 1 MILLÓN DE EUROS
Nuevos inversores de Suecia y España entran en el accionariado de la compañía
AWSensors ha conseguido despertar el interés de inversores nacionales e internacionales y realizar una ronda de 1 millón de euros. En la operación de inversión han participado BeAble Capital, sociedad gestora que tiene como objetivo invertir en empresas de base tecnológica con origen en universidades y centros de investigación españoles, y Tech Transfer UPV, fondo creado específicamente para trasladar al mercado tecnología desarrollada en la Universidad Politécnica de Valencia. Pero también un consorcio de empresas tecnológicas suecas ha apostado fuerte por entrar como inversor en AWSensors. Además, empresas valencianas como PolymerChar, Keodes o Citrosol están también entre los accionistas.
Esta inversión permitirá a AWSensors consolidarse en el mercado científico internacional donde comercializa una nueva tecnología patentada de sensores para análisis de interacciones moleculares en tiempo real que utilizan investigadores de Europa, Estados Unidos y Asia en los campos de ciencias de la vida y nuevos materiales.
La compañía, liderada por el Prof. Antonio Arnau, espera invertir en nueva infraestructura de fabricación y captar nuevo talento para su plantilla. El objetivo es acelerar el proceso de innovación para sacar al mercado nuevos equipos con mayor productividad y automatización e iniciar nuevos desarrollos para el mercado de salud, ya que la tecnología de AWSensors podrá ser aplicada en medicina personalizada.
Uno de los desarrollos previstos para el mercado sanitario es un equipo para la detección precoz de cáncer colorrectal y su monitorización sin necesidad de entrar al quirófano para realizar una biopsia del tumor. Servirá con un análisis de sangre cuyos resultados se podrían obtener en una hora. La detección en este caso se basa en el ADN que libera el tumor en el organismo. El nuevo sistema permitirá detectar ese ADN circulante y las mutaciones que sufre asociadas al cáncer. Este análisis, denominado biopsia líquida, permitirá un control sencillo del paciente y facilitará por tanto la adaptación del tratamiento de forma personalizada.
Este nuevo equipo se está desarrollando junto a otras empresas e instituciones de España, Bélgica, Reino Unido y Grecia dentro del proyecto LiqBiopSens financiado por la Comisión Europea dentro del programa H2020. Un proyecto que ha inyectado medio millón de euros a AWSensors.
Paralelamente a este desarrollo, AWSensors participa en otro proyecto europeo, Catch-u-DNA que investiga una nueva técnica para mejorar la sensibilidad de la tecnología en la detección del ADN circulante. Este proyecto, que se realiza con socios de Alemania, Francia, Israel, Grecia y España, ha supuesto el ingreso de medio millón de euros más en la compañía.
En total, la Comisión Europea ha dotado con 5’7 millones de euros a estos dos proyectos de investigación cuyos resultados impulsarán el crecimiento de AWSensor
In 2015 AWSensors already got the European project “LiqBiopSens” to develop a liquid biopsy platform for early detection and monitoring of colorectal cancer. Now, the company will work in the European project “CATCH-U-DNA”, worth 3.4 million euros. CATCH-U-DNA poses a new concept in biophysics and molecular diagnosis based on acoustic sensing of DNA in serum. It aims to provide a novel technology for the ultrasensitive detection of circulating-tumor DNA in serum without PCR amplification.
“CATCH-U-DNA” project was granted under the Horizon 2020 FET-OPEN call, aimed at financing radically new initiatives that can have a long-term economic and social impact. Only the most cutting-edge technology projects are chosen. It is one of the most competitive European programs, where less than 4 per cent of the ideas presented are funded. The project is coordinated by Prof. Electra Gizeli, leader of the Biosensors group in the Institute of Molecular Biology and Biotechnology of the Greek Foundation for Research and Technology-Hellas (FORTH).
Detection of lung and colorectal cancer
The ultimate goal of “CATCH-U-DNA” is to validate a new, simpler and cheaper technology for the detection of genetic markers so that personalized medical diagnosis can be performed in a more precise, easy and affordable way than current technologies.
The project faces the ambitious challenge of testing that radically new technology in the early diagnosis of cancer by detecting the most common genetic mutations that cause colorectal cancer and lung cancer. In fact, it includes not only experimental research but also clinical trials.
In the future, it will be possible to incorporate this new technique into portable equipment and will therefore allow on-site analysis applied to personalized medicine in developed countries or in areas without laboratory infrastructure such as underdeveloped countries.
New technique easier, more affordable and more precise
The amount of mutated DNA in a sample is generally very low, which greatly hampers its detection and characterization. Most of the current methods of detection are based on the technique known as PCR (polymerase chain reaction), which allows amplifying a fragment of DNA by obtaining millions of copies, thus, its detection in the lab is feasible. However, this technique involves a complex and expensive procedure prior to detection. In addition, it may cause a deviation if the amplification is not developed properly.
The “CATCH-U-DNA” technology promises to overcome these limitations and allow for the genetic analysis of human samples in an easier, more affordable and more precise way. The aim is to manufacture an ultra-sensitive device capable of detecting DNA in human samples without any previous amplification procedure even though the amount of that DNA is minimal. Specifically, the goal is the detection of circulating DNA, fragments from the tumor cells found in the blood.
The new technique will use high frequency quartz crystal sensor arrays that allow for a real-time, label-free monitoring, in combination with a revolutionary DNA identification system based on the hydrodynamic molecular properties. This approach will allow to push the detection limit down obviating the amplification.
7 companies and organizations from 5 different countries
The “CATCH-U-DNA” project will be developed over 3 years. Experts in molecular biology, physics, chemistry, nanomaterials, biosensors and microfluidics from Spain, Germany, France, Greece and Israel are involved. They are from the Greek Foundation for Research and Technology Hellas (FORTH), which is the project coordinator, and from AWSensors; the Autonomous University of Madrid, in Spain; the University of Crete in Greece; the Curie Institute in France; the Ben Gurion University of Negev in Israel and the German company Jobst Technologies.
https://awsensors.com/wp-content/uploads/2015/05/bg1.jpg3401800AWSensorshttps://awsensors.com/wp-content/uploads/2015/07/Logos-AWS-2015-1.pngAWSensors2017-07-24 08:51:482017-09-22 10:37:45New project to validate an easier and faster technique of molecular diagnosis applied to cancer by using quartz sensors
Authors: A. Grammoustianou, G. Papadakis, M. Tabraue, J.J. Díaz-Mochon, R. Fernández, J.V. García, A. Arnau, E. Gizeli. AWSensors S.L., Institute of Molecular Biology and Biotechnology- FORTH, University of Crete, Destina Genomics S.L., Centro de Investigación e Innovación en Bioingeniería – Universidad Politécnica de Valencia
Event: 5th International Conference on Bio-sensing Technology, Riva del Garda, Italy (2017)
In the past decade, the analysis of circulating tumour DNA (ctDNA) in blood has been a major breakthrough; ctDNA has been proposed as a priceless source for cancer diagnostic, prognostic and treatment monitoring through a new methodology known as “Liquid Biopsy”. This study presents a novel diagnostic method for the acoustic detection of KRAS mutations in ctDNAs based on: (1) DNA analysis by “dynamic chemistry” that utilizes aldehyde modified nucleobases (SMART) and abasic peptide nucleic acids (DGL probes) capable for the errorfree detection of nucleic acids and their mutations; and, (2) a high fundamental frequency (100 MHz) acoustic wave microsensor (AWS HFF-QCM) that allows the accurate, inexpensive, label-free and real time monitoring of the “dynamic chemistry”. Surface-immobilized DGL probes on the AWS HFF-QCM device are used to detect ctDNAs of wild type and mutated KRAS variants. Upon hybridization of the DGL probe with its target ssDNA, a duplex is formed where biotin- tagged SMART bases can lock in front of the position under interrogation; streptavidin binding detected in a follow-up step confirms the presence of the SMART bases. The use of DGL probes in combination with an isothermal DNA amplification step RPA) have allowed the sensitive and specific recognition of single mismatches in KRAS genes in less than 1 hour. This work presents a unique and novel technology that can emerge as a promising tool in the field of cancer diagnostics.
Schema for complete detection protocol:
(A) Extracted DNA containing mutant (red) and wild type DNA fragments (black) are enzymatically amplified.
(B) Denatured amplicons are hybridized on surface immobilized DGL probes. Chemical locking of a specific tagged SMART base takes place only in the appropriate position.
(C) Incorporated SMART bases are recognized by streptavidin and monitored in real-time during an acoustic measurement.
https://awsensors.com/wp-content/uploads/2015/07/Logos-AWS-2015-1.png00AWSensorshttps://awsensors.com/wp-content/uploads/2015/07/Logos-AWS-2015-1.pngAWSensors2017-05-12 10:02:112017-09-22 10:51:24A liquid biopsy platform combining a high fundamental frequency QCM device with dynamic chemistry for detecting mutations in circulating DNA
We are proud to announce that the European Comission awarded a grant of a total value of 2’7M euros to our project LIQBIOPSENS for early detection of colorectal cancer by carrying out liquid biopsy. The grant was awarded within Horizon2020 and specifically in the call entitled “ICT-28-2015: Cross cutting ICT Key Enabling Technologies”.
AWSensors will coordinate this H2020 project during the next 3 years (2016-2018). The overall aim of this project is the further development and validation in real settings of a novel diagnostic platform for the early and fast detection of circulating tumor DNA (ctDNA) and their KRAS and BRAF mutations associated to colorectal cancer through blood samples.
Liquid Biopsy platform LiqBiopSens features
The main features of LiqBiopSens are:
Reliability (detection rates vary from 95-100 %)
Low-Cost
Sensitivity (in the zM range)
Multiplexing capabilities (analysis of 27 KRAS and BRAF mutations simultaneously)
Short analysis time (30-60 min.)
User-friendly interface
Flexibility
LIQBIOPSENS platform is based on the integration of two novel complementary technologies:
However, solution proposed by the LIQBIOPSENS project relies on the multidisciplinary integration of different key enabled technologies. Accordingly, LiqBiopSens will be accomplished by AWSensors and Destina Genomics in collaboration with the following partners:
The operating concept of our project is described in the following representative scheme:
ctDNA amplicons produced in chamber (1) are denatured and transferred to the sensors surface via microfluidics (2) where hybridization with DGL probes takes place; mutation‐discrimination is carried out during the injection (3) of novel probes which click selectively on the target DNA (4) while acoustic detection exploits functionalized nanoparticles (5).
Colorectal cancer, the second most common cause of cancer death
The most frequently occurring forms of cancer in the EU are colorectal, breast, prostate and lung cancers. In men, lung cancer is the most frequent cause of cancer death, while in women, it is breast cancer. In both men and women, colorectal cancer is the second most common cause of cancer death.
The “gold standard” for identifying the type and extent of a cancer is a tissue biopsy, in which a small sample of tissue is taken from the suspected tumour and histologically examined. While this procedure can provide important information about the patient disease, tissue biopsy can be painful, represents a single snap-shot in time, is subjected to significant selection bias and if the tumour tested was first detected by palpation or imaging, it may already be so large that the disease is well advanced. Furthermore, when the tumour tissue is removed or it is inaccessible, these genotyping techniques are impossible. Therefore, cancer remains a ghost disease when primary tumours are removed through surgery, meaning that there are not tools to assess the efficiency of treatments or prevent metastasis.
Liquid Biopsy, a revolution in the fight against cancer
It has long been known that solid tumors release DNA in the blood and the load of circulating tumor DNA (ctDNA) has been correlated to staging and prognosis. However, only recent advances in the sensitivity and accuracy of DNA analysis have allowed for genotyping of somatic changes found in tumors by interrogating ctDNA. This technique is known as ‘Liquid Biopsy’ and it is based on the analysis of a biomarker that can be easily isolated from many body fluids (blood, saliva, urine, ascites, pleural effusion, etc.).
Successful implementations of liquid biopsy techniques to track tumor dynamics in real time and for the early detection, such as LIQBIOPSENS, are going to revolutionise how clinicians fight against cancer.
https://awsensors.com/wp-content/uploads/2015/12/DNA.jpg48006400AWSensorshttps://awsensors.com/wp-content/uploads/2015/07/Logos-AWS-2015-1.pngAWSensors2015-12-10 15:51:512017-09-22 11:02:04H2020 Project LiqBiopSens: A new liquid biopsy platform for early detection of colorrectal cancer
From this panel the user will be able to configure the cookies that the website can install in their browser, except for the technical or functional cookies that are necessary for browsing and using the different options or services that are offered.
The selected cookies indicate that the user authorises the installation in their browser and the processing of data under the conditions stated in the Cookie Policy.
The user can check or uncheck as they wish to accept or reject the installation of cookies.
COOKIES CONTROLLED BY THE EDITOR
Analytics
Property
Cookie
Purpose
Term
awsensors.com
_ga
ID used to identify users
in 2 years
awsensors.com
_gat
Used to monitor number of Google Analytics server requests when using Google Tag Manager
Sesión
awsensors.com
_gid
ID used to identify users for 24 hours after last activity
in 20 hours
Marketing
Property
Cookie
Purpose
Term
google.com
NID
This cookies is used to collect website statistics and track conversion rates and Google ad personalisation
in 7 months
HOW TO MANAGE COOKIES FROM YOUR BROWSER
Delete cookies from your device
Cookies that are already on a device can be deleted by clearing the browser history, thus deleting the cookies from all websites visited.
However, some of the saved information (e.g. login data or website preferences) may also be lost.
Manage site specific cookies
For more precise control of site specific cookies, users can adjust their privacy settings and cookies in their browser.
Blocking cookies
While most modern browsers can be configured to prevent cookies from being installed on a device, this may require the manual adjustment of certain preferences each time a site or page is visited. In addition, some services and features may not work properly (for example, profile logins).
Desde este panel podrá configurar las cookies que el sitio web puede instalar en su navegador, excepto las cookies técnicas o funcionales que son necesarias para la navegación y la utilización de las diferentes opciones o servicios que se ofrecen.
Las cookies seleccionadas indican que el usuario autoriza la instalación en su navegador y el tratamiento de datos bajo las condiciones reflejadas en la Política de cookies.
El usuario puede marcar o desmarcar el selector según se desee aceptar o rechazar la instalación de cookies.
COOKIES CONTROLADAS POR EL EDITOR
Analíticas
Propiedad
Cookie
Finalidad
Plazo
awsensors.com
_ga
ID utiliza para identificar a los usuarios
en 2 años
awsensors.com
_gat
Se utiliza para monitorizar el número de peticiones al servidor de Google Analytics cuando se utiliza el Administrador de etiquetas Google
Sesión
awsensors.com
_gid
ID utiliza para identificar a los usuarios durante 24 horas después de la última actividad
en 20 horas
Publicitarias
Propiedad
Cookie
Finalidad
Plazo
google.com
NID
Estas cookies se utilizan para recopilar estadísticas del sitio web y rastrear las tasas de conversión y la personalización de anuncios de Google
en 7 meses
CÓMO GESTIONAR LAS COOKIES DESDE EL NAVEGADOR
Eliminar las cookies del dispositivo
Las cookies que ya están en un dispositivo se pueden eliminar borrando el historial del navegador, con lo que se suprimen las cookies de todos los sitios web visitados. Sin embargo, también se puede perder parte de la información guardada (por ejemplo, los datos de inicio de sesión o las preferencias de sitio web).
Gestionar las cookies específicas del sitio
Para tener un control más preciso de las cookies específicas de cada sitio, los usuarios pueden ajustar su configuración de privacidad y cookies en el navegador.
Bloquear las cookies
Aunque la mayoría de los navegadores modernos se pueden configurar para evitar que se instalen cookies en los dispositivos, eso puede obligar al ajuste manual de determinadas preferencias cada vez que se visite un sitio o página. Además, algunos servicios y características pueden no funcionar correctamente (por ejemplo, los inicios de sesión con perfil).
CÓMO ELIMINAR LAS COOKIES DE LOS NAVEGADORES MÁS COMUNES
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
Las cookies estrictamente necesarias tiene que activarse siempre para que podamos guardar tus preferencias de ajustes de cookies.
Básicamente la web no funcionará bien si no las activas.
Estas cookies son:
Comprobación de inicio de sesión
Cookies de seguridad
Aceptación/rechazo previo de cookies
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.
Si desactivas esta cookie no podremos guardar tus preferencias. Esto significa que cada vez que visites esta web tendrás que activar o desactivar las cookies de nuevo.
3rd Party Cookies / Cookies de terceros
Third-party services are beyond the control of the editor. Suppliers may at any time modify their service conditions, the purpose and use of cookies, etc.
Used to monitor number of Google Analytics server requests when using Google Tag Manager
Sesión
awsensors.com
_gid
ID used to identify users for 24 hours after last activity
in 20 hours
Marketing
Property
Cookie
Purpose
Term
google.com
NID
This cookies is used to collect website statistics and track conversion rates and Google ad personalisation
in 7 months
COOKIES DE TERCEROS
COOKIES CONTROLADAS POR EL EDITOR
Los servicios de terceros son ajenos al control del editor. Los proveedores pueden modificar en todo momento sus condiciones de servicio, finalidad y utilización de las cookies, etc.